Literature DB >> 25805924

Updates in vaccination: recommendations for adult inflammatory bowel disease patients.

Khadija Chaudrey1, Michelle Salvaggio1, Aftab Ahmed1, Sultan Mahmood1, Tauseef Ali1.   

Abstract

Treatment regimens for inflammatory bowel disease (IBD) incorporate the use of a variety of immunosuppressive agents that increase the risk of infections. Prevention of many of these infections can be achieved by the timely and judicious use of vaccinations. IBD patients tend to be under-immunized. Some of the contributing factors are lack of awareness regarding the significance of vaccinating IBD patients, misperception about safety of vaccinations in immunocompromised patients, ambiguity about the perceived role of the gastroenterologist in contrast to the primary care physician and unavailability of vaccination guidelines focused on IBD population. In general, immunocompetent IBD patients can be vaccinated using standard vaccination recommendations. However there are special considerations for IBD patients receiving immunosuppressive therapy, IBD travelers and pregnant women with IBD. This review discusses current vaccination recommendations with updates for adult IBD patients. Centers for Disease Control and Prevention 2013 vaccination guidelines with 2014 updates and the Advisory Committee on Immunization Practices recommendations have been highlighted as a primary source of recommendations.

Entities:  

Keywords:  Centers for Disease Control and Prevention; Immunocompromised; Influenza; Inflammatory bowel disease; Pneumococcal; Vaccination

Mesh:

Substances:

Year:  2015        PMID: 25805924      PMCID: PMC4363747          DOI: 10.3748/wjg.v21.i11.3184

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  74 in total

1.  Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab.

Authors:  Jonathan Moses; Naim Alkhouri; Angela Shannon; Ariel Feldstein; Christine Carter-Kent
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

2.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

3.  A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group.

Authors:  M Feeney; A Ciegg; P Winwood; J Snook
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

4.  Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression.

Authors:  Seper Dezfoli; Gil Y Melmed
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-08

5.  Crohn's disease, measles, and measles vaccination: a case-control failure.

Authors:  N P Thompson; D M Fleming; R E Pounder; A J Wakefield
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

Review 6.  The epidemiology of genital human papillomavirus infection.

Authors:  Helen Trottier; Eduardo L Franco
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

7.  Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.

Authors:  Iris Dotan; Lael Werner; Sharon Vigodman; Shradha Agarwal; Jorge Pfeffer; Noya Horowitz; Lisa Malter; Maria Abreu; Thomas Ullman; Hanan Guzner-Gur; Zamir Halpern; Lloyd Mayer
Journal:  Inflamm Bowel Dis       Date:  2011-03-15       Impact factor: 5.325

8.  Lack of association between cervical dysplasia and IBD: a large case-control study.

Authors:  C W Lees; J Critchley; N Chee; T Beez; R E Gailer; A R Williams; A G Shand; I D R Arnott; J Satsangi
Journal:  Inflamm Bowel Dis       Date:  2009-11       Impact factor: 5.325

9.  Would CLSI M53-A have helped in the diagnosis of HIV in Canada? Results of the performance of Canadian laboratories participating in a recent NLHRS proficiency testing panel containing HIV-1 antigen positive (antibody negative) and HIV-2 samples.

Authors:  K Kadivar; L Malloch; Y Adonsou-Hoyi; D Ng; S Lavoie; K Pulido; J Kim
Journal:  J Clin Virol       Date:  2013-07-26       Impact factor: 3.168

10.  Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital.

Authors:  Yolanda Faia Manhaes Tolentino; Homero Soares Fogaca; Cyrla Zaltman; Lia Laura Lewis Ximenes; Henrique Sergio Moraes Coelho
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

View more
  8 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

2.  Serious and Opportunistic Infections in Elderly Patients With Inflammatory Bowel Disease.

Authors:  Elissa Lin; Kevin Lin; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-11

3.  [Guidelines for vaccination of immunocompromised individuals].

Authors:  Ursula Wiedermann; Harald H Sitte; Heinz Burgmann; Alexander Eser; Petra Falb; Heidemarie Holzmann; Maria Kitchen; Marcus Köller; Herwig Kollaritsch; Michael Kundi; Hans Lassmann; Ingomar Mutz; Winfried F Pickl; Elisabeth Riedl; Maria Sibilia; Florian Thalhammer; Barbara Tucek; Werner Zenz; Karl Zwiauer
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

4.  Using Computerized Physician Order Entry to Ensure Appropriate Vaccination of Patients with Inflammatory Bowel Disease.

Authors:  Jacob R Karr; Jonathan J Lu; Robert B Smith; Austin C Thomas
Journal:  Ochsner J       Date:  2016

Review 5.  OMIC Technologies and Vaccine Development: From the Identification of Vulnerable Individuals to the Formulation of Invulnerable Vaccines.

Authors:  Nicola Cotugno; Alessandra Ruggiero; Veronica Santilli; Emma Concetta Manno; Salvatore Rocca; Sonia Zicari; Donato Amodio; Manuela Colucci; Paolo Rossi; Ofer Levy; Federico Martinon-Torres; Andrew J Pollard; Paolo Palma
Journal:  J Immunol Res       Date:  2019-04-28       Impact factor: 4.818

6.  A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease.

Authors:  Guillaume Le Cosquer; Lionel Grangeon; Pauline Rivière; Arthur Berger; Frank Zerbib; David Laharie; Florian Poullenot
Journal:  Therap Adv Gastroenterol       Date:  2022-04-20       Impact factor: 4.802

Review 7.  Preventive health measures in inflammatory bowel disease.

Authors:  Ayokunle T Abegunde; Bashir H Muhammad; Tauseef Ali
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

8.  Vaccination status of patients using anti-TNF therapy and the physicians' behavior shaping the phenomenon: Mixed-methods approach.

Authors:  Hussain Abdulrahman Al-Omar; Hadeel Magdy Sherif; Ahmed Yaccob Mayet
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.